GF58573648
Lutetium
powder, 1g, max. particle size 500 micron, 99.9%
Synonym(s):
Lutetium, LU006010
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
Lu
CAS Number:
Molecular Weight:
174.97
MDL number:
UNSPSC Code:
11101711
PubChem Substance ID:
NACRES:
NA.23
Recommended Products
assay
99.9%
form
powder
manufacturer/tradename
Goodfellow 585-736-48
resistivity
54 μΩ-cm, 20°C
particle size
500 μm
bp
3402 °C (lit.)
mp
1663 °C (lit.)
density
9.84 g/mL at 25 °C (lit.)
SMILES string
[Lu]
InChI
1S/Lu
InChI key
OHSVLFRHMCKCQY-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
signalword
Danger
hcodes
Hazard Classifications
Flam. Sol. 1
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R O Perez et al.
Techniques in coloproctology, 18(8), 699-708 (2014-02-11)
Molecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant
B L R Kam et al.
European journal of nuclear medicine and molecular imaging, 39 Suppl 1, S103-S112 (2012-03-06)
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The
S Panigone et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 50(4), 310-321 (2006-10-18)
Optimization of therapy for individual patients remains a goal of clinical practice. Radionuclide imaging can identify those patients who may benefit from subsequent targeted therapy by providing regional information on the distribution of the target. An ideal situation may be
Constantin Lapa et al.
Nuclear medicine and biology, 42(4), 349-354 (2015-01-18)
Peptide receptor radionuclide therapy (PRRT) is a treatment option for both iodine-refractory differentiated and advanced medullary thyroid cancer (TC). It requires over-expression of somatostatin receptor subtype II (SSTR) that can be non-invasively assessed by positron emission tomography (PET). Assessment of
Constantin Lapa et al.
Annals of medicine, 47(7), 538-545 (2015-10-30)
Brown adipose tissue (BAT) attracts growing interest as a potential therapeutic target for obesity and diabetes. Hyperthyroidism is well-known to increase BAT activity, but the role of hypothyroidism is controversial. We aimed to investigate the association between different thyroid hormone
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service